Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RDEA3170 and Febuxostat in Japanese Men with Gout or Asymptomatic Hyperuricemia
NCT02317861Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of verinurad in gout and hyperuricemia (6 cohorts), sponsored by AstraZeneca. Primary endpoints: Change in Serum uric acid level at Day 7, Change in Urinary excretion of uric acid at Day 7 and 2 more. Started Dec 2014; status: completed.
02
Drugs
verinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT02317861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317861.